Bavarian Nordic A/S reported preliminary, unaudited financial results for the full year 2025, with revenue reaching DKK 6,244 million, exceeding the latest guidance of approximately DKK 6,000 million. EBITDA excluding other net operating income was DKK 1,732 million, corresponding to an EBITDA margin of 28%, while EBITDA including other net operating income totaled DKK 2,542 million, representing an EBITDA margin of 41%. Other net operating income amounted to DKK 810 million, primarily driven by the sale of a Priority Review Voucher. The company highlighted strong performance in its Travel Health segment, which grew 30% year-over-year, mainly supported by its core vaccines for rabies and tick-borne encephalitis, as well as the successful launch of its chikungunya vaccine. Bavarian Nordic A/S remains the leading provider of mpox and smallpox vaccines to governments for public health responses and stockpiling. For 2026, the company expects revenue between DKK 5,000 million and DKK 5,200 million and an EBITDA margin of approximately 25%. The financial results for 2025 are preliminary and unaudited, with the audited figures scheduled for release in March 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bavarian Nordic A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001164369-en) on February 12, 2026, and is solely responsible for the information contained therein.